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Abstract
The ability of CD4+Foxp3+ regulatory T-cells (Treg) to produce interleukin (IL)-10 is important for the limitation of
inflammation at environmental interfaces like colon or lung. Under steady state conditions, however, few Tregs produce IL-
10 ex vivo. To investigate the origin and fate of IL-10 producing Tregs we used a superagonistic mouse anti-mouse CD28
mAb (CD28SA) for polyclonal in vivo stimulation of Tregs, which not only led to their numeric expansion but also to a
dramatic increase in IL-10 production. IL-10 secreting Tregs strongly upregulated surface receptors associated with
suppressive function as compared to non-producing Tregs. Furthermore, polyclonally expanding Tregs shifted their
migration receptor pattern after activation from a CCR7+CCR52 lymph node-seeking to a CCR72CCR5+ inflammation-
seeking phenotype, explaining the preferential recruitment of IL-10 producers to sites of ongoing immune responses.
Finally, we observed that IL-10 producing Tregs from CD28SA stimulated mice were more apoptosis-prone in vitro than their
IL-10 negative counterparts. These findings support a model where prolonged activation of Tregs results in terminal
differentiation towards an IL-10 producing effector phenotype associated with a limited lifespan, implicating built-in
termination of immunosuppression.
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Introduction
CD4+Foxp3+ regulatory T-cells (Tregs) are essential for the
maintenance of immunological homeostasis and self tolerance [1].
They control unwanted immune responses by a number of distinct
mechanisms, which differentially contribute to suppression
depending on the experimental settings studied [2]. One key
element in the regulation and execution of Treg activity is
interleukin (IL)-2. Thus, IL-2 produced by ‘‘conventional’’ T-cells
(Tconvs) drives Treg expansion and boosts regulatory function,
including production of the suppressive cytokine IL-10 [3]. At the
same time, Tregs act as an ‘‘IL-2 sink’’ [4] since they do not
produce IL-2 themselves [5] but consume IL-2 produced by
Tconvs.
IL-10 produced by several innate and adaptive immune cells is a
key immunosuppressive and anti-inflammatory cytokine as illus-
trated by the spontaneous lethal inflammatory bowel disease of IL-
10-deficient mice [6]. IL-10-mediated control of immune homeo-
stasis has been associated with several CD4+ T-cell subsets defined
by their anatomical origin or mode of generation like Foxp32IL-
10+ Tr1 (T regulatory type-1), Tr1-like cells and Foxp3+ Tregs, the
latter being the subject of the present paper. Foxp3+ Tregs can
develop in the thymus or in the periphery from naı¨ve CD4+ T-cell
precursors [7]. In vitro studies failed to show a requirement for IL-
10 in the inhibition of T-cell responses [8]. In contrast, Foxp3+
Treg derived IL-10 contributes to immune regulation in vivo,
although not in all settings studied [2]. Selective IL-10 deficiency
in Tregs results in spontaneous colitis and inflammation in skin
and lung [9].
To locally suppress unwanted immune responses and inflam-
mation, Tregs must migrate to lymphoid organs and inflamed
tissues [10]. Homing and trafficking are controlled by adhesion
molecules and chemokine receptors [11]. Consequently naı¨ve
Tregs express CD62L and CCR7, allowing them to recirculate
through lymphoid tissues. Upon activation, Tregs upregulate
inflammatory chemokine receptors (CCR2, CCR5, CCR6,
CXCR3), selectin ligands (E- and P-selectin ligand) and integrins
(CD103), directing them to inflamed sites [12,13]. Accordingly,
IL-10 producing Tregs are mainly found at sites of ongoing
immune responses [7].
In a healthy immune system, the balance between Tregs and
Tconvs is controlled by mechanisms which mutually control
survival and proliferation of both types of T-cells, e.g., even in an
apparently resting immune system, the survival of Tregs in the
periphery is controlled by common gamma chain cytokines
(mainly IL-2) derived from Tconvs [14], and by costimulatory
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signals via CD28 [15]. During an immune response, Treg
expansion follows that of Tconvs, and is driven by antigen
recognition and by excess IL-2 produced by the activated
conventional CD4+ T-cells. Both populations of T-cells clonally
contract once the antigen has been eliminated [16].
In contrast to clonal expansion of rare Treg clones, synchronous
activation of a large number of Tregs allows for a more
comprehensive characterisation of their phenotype, function, and
migrational behaviour. In order to follow such a synchronous
wave of polyclonal Treg activation in vivo, we have used
stimulation with superagonistic mouse anti-mouse CD28 mAb
(CD28SA). We and others have previously shown that such mAb
are effective expanders and activators of Tregs in rats [17,18] and
mice [19,20,21], allowing interference with multiple model
diseases of autoimmunity, graft rejection and inflammation [22].
CD28SA differ from conventional CD28-specific antibodies by
their ability to activate T-cells without T-cell receptor (TCR)
ligation by amplifying weak or ‘‘tonic’’ TCR signals [23,24]. In
vitro and in vivo, they act on both Tconvs and Tregs; the IL-2
produced by Tconvs in response to CD28SA stimulation is
immediately utilized by Tregs [19], which respond with expansion
and functional activation including IL-10 production [17,18,25].
This single wave of polyclonal Treg activation effectively controls
the expression of effector functions and toxic cytokine release by
Tconvs, which were also initially triggered [19], and is terminated
by clonal contraction within two weeks after CD28SA application
[19,23].
Whereas it has long been accepted that IL-10 can be used by
Tregs to suppress immune responses, there is only little known
about the function and fate of Tregs with an IL-10 producing
phenotype. In the present study we observed that IL-10 producing
Tregs are derived from non-IL-10 producing Tregs. They are
highly activated suppressor cells migrating to inflamed tissues.
Furthermore the IL-10-producing phenotype is associated with an
increased sensitivity to apoptosis. We suggest that IL-10 producing
Tregs represent a fully activated stage of terminal differentiation
with a limited life-span, which facilitates the return to immuno-
logical normality after clearance of an infection.
Results
CD28SA application induces IL-10 production in Tregs
Tregs can be expanded and functionally activated by a single
injection of the mouse anti-mouse superagonistic CD28 mAb
D665 [19,25]. We injected a saturating dose (200 mg/mouse, [19])
of CD28SA i.p. into C57BL/6 mice and followed Treg expansion
and IL-10 production in lymph nodes. In unstimulated mice
between 5 and 10% of the CD4+ T-cell population were Foxp3+
Tregs (Fig. 1A). Three days after CD28SA injection, their
frequency increased up to six-fold and their absolute cell numbers
up to 15-fold compared to control values (Fig. 1B and 1C).
Whereas few IL-10 secreting Tregs are found in an apparently
resting immune system, we observed a dramatic increase (125-fold)
after administration of CD28SA (Fig. 1A–1C). The response to
CD28SA peaked on day 3 to 4, and cell numbers went back to
normal levels within 8 days (Fig. 1B and [19]). Transfer of Foxp3-
depleted Thy1.2+ CD4+ T-cells from DEREG mice into Thy1.1
mice revealed that the increase in IL-10 production and Treg
number three days after CD28SA treatment is mainly the result of
expansion of pre-existing Treg cells, rather than conversion from
CD4+ Tconv (Fig. 1D).
The high frequency of IL-10 producing Tregs in CD28SA
treated mice allowed us to further investigate the origin and fate of
these polyclonally stimulated Tregs. To examine the relationship
between IL-10 production and the proliferative history of Tregs,
we transferred CFSE-labeled CD4+ T-cells from Thy1.1 mice into
congenic C57BL/6 mice. 24 hours later animals were treated with
CD28SA, and after three days the progeny of transferred cells
were analysed for the expression of Foxp3 and IL-10. Both
conventional and Foxp3+ CD4+ T-cells proliferated, but Tregs
proliferated more extensively than conventional CD4+ T-cells,
most likely because of the counter-regulation exerted by Tregs
(Fig. 1E and [22]). Importantly, IL-10 expression in Tregs was
most prominent in cells that had undergone several cell divisions
(Fig. 1E). Together with the kinetic data (Fig. 1B) this suggests
that in response to in vivo stimulation with CD28SA, Tregs initially
expand before they switch on IL-10 production.
Suppressive capacity of IL-10+ CD28SA-activated Tregs
To further characterize the IL-10 producing and non-producing
Treg subsets recovered three days after polyclonal in vivo activation
with CD28SA, we phenotyped CD4+ T-cells by surface marker
expression (Fig. 2). Unstimulated as well as stimulated Foxp3+ T-
cells expressed a memory-like phenotype, i.e. in comparison to
Tconvs (Foxp32), they expressed high levels of CD44 and low
levels of CD45RB. In addition, the functionally important Treg
surface receptors CD25, CTLA-4, GITR and ICOS were further
upregulated in Tregs from CD28SA stimulated mice. Interesting-
ly, cell surface molecules associated with effector function of Tregs
like CD39, PD-1, LAP, CD25 or CTLA-4 were expressed at even
higher levels in IL-10 producing than in IL-10 negative Tregs,
where upregulation was up to 20-fold (for CTLA-4) as compared
to unstimulated Tregs (Fig. 2).
To compare the suppressive activity of the in vivo expanded IL-
10+ and IL-102 Tregs from CD28SA stimulated mice,
CD4+CD25+ cells were separated by FACS into IL-10+ and IL-
102 cells using an IL-10 capture assay. Alternatively IL-
10+Foxp3+ and IL-102Foxp3+ Tregs were FACS sorted from
DEREG Foxp3-reporter mice [26]. These cell fractions were then
cultured with purified CFSE-labeled CD4+CD252 cells as
responders, irradiated APCs and anti-CD3 as a proliferative
stimulus. As controls, unseparated CD4+CD25+ or CD4+Foxp3+
T-cells from unstimulated and CD28SA stimulated mice were
included. In comparison to Tregs from unstimulated mice,
CD28SA stimulated Tregs showed a more than tenfold higher
suppressive activity (Fig. 3A, 3C and [19]). Both IL-10+ and IL-
102 Tregs were highly suppressive, with a higher activity in the IL-
10+ Treg population (Fig. 3A–D), in line with the elevated
expression of Treg effector molecules by this subset (Fig. 2). As
expected from the literature, failure of the anti-IL-10R blocking
mAb to relieve inhibition confirmed that IL-10 itself is not an
important factor in this in vitro setting (Fig. 3E and [7,8]).
Together, these results confirmed that in vivo pretreatment with the
mouse CD28SA upregulates effector function of Tregs [19,20,21]
and show that their high in vitro efficacy is associated with, but not
dependent on, IL-10 production.
CD28SA stimulated Tregs migrate to inflamed sites
Treg migration to sites of ongoing immune responses is
dependent on surface expression of chemokine receptors and
adhesion molecules. Receptors like CCR5, CCR6 or CD103
direct cells to inflamed tissues, whereas CCR7 and CD62L are
associated with lymph node homing [12,13]. Here, we analyzed
whether in vivo activated IL-10 secreting Tregs express the
appropriate receptors for migration to inflamed tissues (Fig. 4A
and S1). In lymph nodes of unstimulated mice about 35% of the
total Treg population expressed CD103 and only about 10%
expressed CCR5 or CCR6. In agreement with published data
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most of the Tregs expressed CCR7, and approximately 40%
expressed CD62L [11]. After injection of CD28SA the pattern of
migration receptors on Tregs shifted. Whereas the fraction of total
Tregs expressing CD103 (minor change) and CD62L (increase
from 40% to 60%) were not dramatically altered, there was a
major change in the expression profile of CCR5, CCR6 and
CCR7. The frequency of Tregs expressing the lymphoid homing
receptor CCR7 was strongly decreased (from about 70% to 20–
10% CCR7+ cells) after 3 to 4 days of CD28SA injection whereas
those expressing CCR5 or CCR6, receptors for migration into
inflamed tissues, were strongly increased (from about 10% to 50%
CCR5+ or CCR6+ cells).
If IL-10 producing Tregs are activated, tissue-seeking descen-
dants of non IL-10 producing cells in a resting immune system, a
shift in migration markers should also be visible between these
populations in unstimulated mice. Indeed comparing the small
population of endogenous IL-10 producing with non-producing
Tregs, we found that the former contained a higher proportion of
tissue homing CD103+, CCR6+ and CCR5+ cells than non IL-10
secreting Tregs (Fig. 4A and data not shown). Also after in vivo
stimulation with CD28SA, IL-10-producers contained a signifi-
cantly higher fraction of CCR5+, CCR6+ and CD103+ cells than
IL-10 non-producers (Fig. S1). Accordingly, the initial drop in the
frequency of CD103+ among IL-10+Foxp3+ cells after CD28SA
simulation (Fig. 4A) is likely due to a delay in CD103 expression
following the induction of IL-10 expression. Regardless of IL-10
production however, CCR7 was downregulated in all Foxp3+
cells. From these data (Fig. 1B, 1E, 4A) we hypothesized that
upon activation, Tregs initially proliferate, downregulate CCR7,
then start to secrete IL-10 and upregulate CCR5 and CCR6 to
finally migrate into inflamed tissues.
To test this directly, a sponge implant containing heat-killed
Listeria monocytogenes was inserted under the skin of C57BL/6 mice
to induce inflammation. 4 days later mice were treated with
Figure 1. IL-10 and Foxp3 expression in CD4+ LN T-cells of untreated or CD28SA treated C57BL/6 mice. (A) IL-10 and Foxp3 expression
in unstimulated mice and in mice 3 days after CD28SA treatment. (B) Kinetics of subsets defined by CD8, CD4, Foxp3 and IL-10 expression 0 to 8 days
after CD28SA injection. (C) Fold change in cell numbers between day 0 and day 3 after stimulation. Graphs show means 6 SD from 3 mice assayed
individually and results are representative of three independent experiments. (D) Lack of conversion of CD4+ Tconv after CD28SA treatment. Sorted
Thy1.2+CD4+ Foxp32 cells from DEREG mice were transferred into naı¨ve Thy1.1 mice one day before CD28SA injection. Three days later Thy1.2+ cells
were analysed for Foxp3 and IL-10 expression. Graphs show means 6 SD from 4 mice assayed individually and results are representative of two
independent experiments. (E) Proliferative history and expression of Foxp3 and IL-10. CFSE-labeled CD4+ T-cells from Thy1.1 mice were transferred
into naı¨ve C57BL/6 mice one day before CD28SA injection. Three days later Thy1.1+ cells were analysed for proliferation, Foxp3 and IL-10 expression.
Flow cytometric analysis of transferred T-cells with average numbers of cell division (acd) (left) and percentage of IL-10 producers within Foxp3+ cells
per generation (right) are depicted. Data represent pooled cells from two mice, and results are representative of three independent experiments.
doi:10.1371/journal.pone.0050080.g001
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CD28SA to expand Tregs. After one week sponges were removed
and immigrated CD4+ T-cells were analysed for IL-10 and Foxp3
expression. Leukocytes recovered from sponges of untreated mice
contained only few CD4+ T-cells within a monocyte/lymphocyte
gate (0.87%60.17), which were increased by 2–3 fold in the
CD28SA-treated group (2.21%60.33) (Fig. 4B). In both groups,
about 40% of CD4+ T-cells were Foxp3+ and about one third of
Foxp3+ cells produced IL-10, indicating that this phenotype is,
indeed, inflammation seeking. In contrast to their enrichment at
the site of inflammation, IL-10 producing Tregs were rare in the
lymph nodes of PBS treated mice (about 1% of Foxp3+), but
strongly increased after CD28SA-driven activation (about 25% of
Foxp3+) (Fig. 4B). These data are best explained by preferential
recruitment of IL-10 producers or at least IL-10 competent Tregs
to the site of inflammation, resulting in a high local frequency of
IL-10 producers even if only few are found in unstimulated
secondary lymphoid tissue.
IL-10 producing Tregs are not a stable subpopulation
The hypothesis that the steep increase in Tregs poised to release
IL-10 observed after in vivo treatment with CD28SA is due to
conversion from a Foxp3+IL-10 non-producer to a Foxp3+IL-10
producer phenotype was directly addressed both in vitro and in vivo
by separating IL-10 producers from non-producers and following
their fate.
To obtain IL-10+Foxp3+ and IL-102Foxp3+ Tregs of high
purity, DEREG Foxp3-reporter mice [26] were treated with
CD28SA three days earlier. CD4+ T-cells were cultured over night
under optimized conditions of stimulation (anti-CD3/anti-CD28
costimulation and IL-2) increasing the recovery of IL-10 producers
detected by a capture assay. Unseparated and FACS-separated
cells were further cultured with anti-CD3/anti-CD28 plus IL-2 for
three days, and analysed each day for the capacity to produce IL-
10 after restimulation with PMA/Ionomycin. While initially,
recovery of Foxp3 expressing cells declined in all three groups by
Figure 2. Phenotype of IL-10+ and IL-102 Tregs 3 days after CD28SA treatment. DMFI (mean fluorescence intensity) ( = MFI(marker)2M-
FI(isotype)) of memory and Treg specific markers on unstimulated or on day 3 stimulated CD4+ T-cell subsets defined by Foxp3 and/or IL-10
expression. Graphs show means 6 SD from 4–8 mice and results are representative of two independent experiments. * p,0.05, ** p,0.005, ***
p,0.001, ns: no significant difference.
doi:10.1371/journal.pone.0050080.g002
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about 50%, unseparated and IL-10-depleted Treg numbers
stabilized on day 2 and then increased again (Fig. 5A). In
contrast, viable Tregs derived from IL-10 producers declined
further, resulting in only 20% recovery on day 3. Besides declining
in number, however, the vast majority of initially IL-10-producing
Tregs also ceased to produce this cytokine, resulting in a decline
from 90% to 20% within 2 days (Fig. 5B and 5C). In contrast, a
significant fraction (20%) of initially IL-10 negative Tregs became
IL-10 producers within the first day of culture. Thus under
optimal in vitro stimulation conditions, IL-10 producing Tregs
declined both in number and in their capability to produce IL-10,
whereas initially IL-10-negative Tregs survived better and gave
rise to new IL-10 producers.
To test the latter conclusion in an in vivo setting, total and IL-
102 CD4+ T-cells from CD28SA pretreated Thy1.1 mice
(containing 27% and 20% Foxp3+ cells, respectively), were labeled
with CFSE and transferred into congenic C57BL/6 mice which
were treated with CD28SA 24 hours later to further stimulate
expansion and IL-10 production. Analysis of lymph node cells
after three days showed that mainly Foxp3+ cells had proliferated
(Fig. 5D), and that virtually all IL-10 producers expressed Foxp3.
Interestingly, the proportion of IL-10+ cells among Tregs was even
higher in mice which had received CD4+ T-cells depleted of IL-10
producers as compared to those receiving unseparated CD4+ T-
cells (12.3% vs. 6.32% IL-10+ among Foxp3+, 4.38% vs. 1.24%
IL-10+ among CD4+), indicating their efficient de novo differen-
Figure 3. Suppressive activity of Treg subsets. (A) Isolated CD4+CD25+ Tregs from CD28SA treated mice were analysed for IL-10 production
using IL-10 Secretion Assay. FACS separated IL-10+ (solid black line) and IL-102 CD4+CD25+ Tregs (dashed black line) were incubated with CFSE-
labeled naı¨ve CD4+CD252 effector T-cells (Teff), (ratio Teff: Treg 1:1 to 81:1) and irradiated APC in the presence of anti-CD3 for 3 days. Stimulated total
CD4+CD25+ Tregs (solid grey line) and CD4+CD25+ Tregs from untreated mice (dashed grey line) were used as controls. (B) Bar graph of IL-10+ (white
bar) and IL-102 CD4+CD25+ Tregs (black bar) with statistical analysis. (C and D) like (A and B) but with FACS sorted Foxp3+ of unstimulated and
CD28SA stimulated DEREG mice. (E) Suppression is IL-10 independent. Blocking anti-IL-10R mAb (10 mg/ml, grey line) was added to cultures with
stimulated (solid line) and unstimulated total CD4+CD25+ Tregs (dashed line). Graphs show average numbers of cell division (acd, mean6 SD) from 3
wells assayed individually and results are representative of three independent experiments. * p,0.05, ** p,0.005, *** p,0.001, ns: no significant
difference.
doi:10.1371/journal.pone.0050080.g003
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tiation from IL-102 precursors (Fig. 5D). More than 90% of IL-
10 producers in both groups had proliferated, similar to results
obtained with transferred naive CD4+ T-cells (Fig. 1E). Taken
together, IL-10 production by Tregs is not a stable phenotype in
vitro or in vivo. Rather, IL-10 production is acquired after clonal
expansion and differentiation towards a tissue-seeking phenotype.
IL-10 producing Tregs are apoptosis-prone
The continuous decline of viable cells recovered from optimally
stimulated cultures of IL-10-producing Tregs (Fig. 5A) suggested
that this high degree of functional activation is accompanied by
increased sensitivity to apoptosis, thereby self-limiting immuno-
suppression. We therefore followed purified IL-10 producing and
non-producing Tregs (the same cultures as analyzed in Fig. 5A)
with regard to the expression of an apoptotic phenotype over time
(Fig. 6A). Indeed, we observed a continuous increase of Annexin
V and 7AAD positive cells, whereas their frequency stabilized in
cultures derived from IL-102 Tregs after the first day of culture
(Fig. 6A).
To further characterize pre-apoptotic cells, we developed a
novel mAb, 10-7A, which binds to phospholipids (phosphatidyl-
ethanolamine, phosphatidylserine and cardiolipin) exposed on
such cells at the outer leaflet of the plasma membrane (Fig. S2A,
B). As shown in Figure 6B, this mAb detects most Annexin V
reactive cells, but provides superior resolution. In fact, ex vivo
staining of CD28SA activated lymph node cells for exposed
phospholipids revealed that IL-10 producing Tregs express much
higher levels as compared to IL-10 non-producers and conven-
tional CD4+ T-cells (Fig. 6C).
Finally, the hypothesis that IL-10 secreting Tregs are more
apoptosis-prone than their IL-10-negative counterparts was
further tested by gene expression analysis. Several pro-apoptotic
genes like Caspase 3, Pten, Bcl2l11 (Bim), Rock1 or Apaf1 were
upregulated in IL-10 producing compared to IL-10 negative
Figure 4. Migration potential of Tregs after CD28SA injection. (A) Flow cytometric analysis of homing related receptors in IL-10+Foxp3+
(black line), IL-102Foxp3+ (grey line) and total Foxp3+ (dashed line) Tregs of mice 0 to 4 days after CD28SA treatment. (B) Migration of Tregs in vivo. A
small piece of sponge containing heat-killed Listeria monocytogenes was placed under the skin of C57BL/6 mice. After 4 days mice were treated with
CD28SA or PBS. On day 7 cells washed out of sponges were stained for CD4, IL-10 and Foxp3 and compared with CD4+ gated LN cells. Graphs show
means 6 SD from 3 mice assayed individually and results are representative of two independent experiments.
doi:10.1371/journal.pone.0050080.g004
Fate of Polyclonally Activated Regulatory T-Cells
PLOS ONE | www.plosone.org 6 November 2012 | Volume 7 | Issue 11 | e50080
Tregs, whereas the anti-apoptotic gene Bcl-2 was downregulated
(Fig. 6D and S3A), a finding which was confirmed by flow
cytometric measurement at the protein level (Fig. 6E).
Discussion
Here we report that Tregs polyclonally activated with CD28SA
in vivo not only dramatically expand in numbers, but also initiate
IL-10 production and upregulate effector molecules and homing
receptors guiding them to inflamed tissue. Furthermore, suppres-
sion was self-limiting as IL-10 production was followed by
apoptosis of the effector Tregs.
Previous work by others has shown that in vitro, a fraction of
Tregs acquires competence for IL-10 production after several
rounds of cell division driven by TCR plus IL-2 stimulation [3,4].
Here, we show that this conversion also occurs, and with an even
higher efficiency, during polyclonal Treg stimulation in vivo, where
it also depends on previous cycling. Thus, proliferating Tregs in
CD28SA stimulated mice initially contained only very few (,2%)
IL-10 producers, but this proportion dramatically increased to
about 25% by day 3, with peak frequencies in Tregs having
undergone 5–7 cell divisions (Fig. 1). Furthermore, FACS-sorted
non-IL-10 producing Tregs restimulated in vivo via CD28SA
initiate IL-10 secretion (Fig. 5D). By transfer experiments we
could demonstrate that conversion of Tconv into Foxp3+ and/or
IL-10+ cells does not contribute to the enriched numbers of IL-10+
Foxp3+ cells in our system (Fig. 1D). Mechanistically, the in vitro
and in vivo observations on IL-10 induction in Tregs are most likely
equivalent because CD28SA amplifies weak TCR signals [24],
and IL-2 is provided by concomitant stimulation of conventional
CD4+ T-cells [19]. Treg conversion from an IL-10 incompetent to
an IL-10 competent phenotype was also observed in vivo using
Foxp3/IL-10 reporter mice under steady-state conditions [7].
Since Tregs undergo continuous homeostatic turnover, this is not
in contrast to our conclusion that cell division precedes expression
of IL-10.
Both in resting [7] and in CD28SA stimulated mice (Fig. 2), IL-
10 competent Tregs have features of activated or memory T-cells
(CD44high, CD45RBlow, GITRhigh, ICOShigh). Importantly, IL-10
producing Tregs from CD28SA stimulated mice were particularly
high in the expression of regulatory effector molecules which was
most prominent for CTLA-4 with a 2.5-fold higher expression
than on their IL-10 negative counterparts, and a 20-fold
upregulation above the constitutive level on resting Tregs
(Fig. 2). Recently, the importance of this receptor for Treg
Figure 5. Instability of IL-10 producing phenotype in vitro and in vivo. (A–C) Phenotypic changes during in vitro proliferation. CD4+CD25+
Tregs of CD28SA treated DEREG mice were isolated and stimulated over night with anti-CD3, anti-CD28 and IL-2. Next day cells were stained for IL-10
and separated into IL-10+Foxp3+ (black line) and IL-102Foxp3+ (grey line) via FACS Sorter. Isolated cells where cultured for 1 to 3 days with anti-CD3,
anti-CD28, IL-2 and examined for cell numbers of Foxp3+ cells (A), of IL-10+Foxp3+ cells (B) and for percentage of IL-10 producers (C). As a control,
unseparated CD4+CD25+ T-cells (dashed line) were used. Graphs show means 6 SD of 3 individual experiments. *** p,0.001 compared IL-10+Foxp3+
to IL-102Foxp3+ cells. (D) In vivo conversion. CFSE labeled total CD4+ T-cells or IL-102CD4+ T-cells of Thy1.1 mice 3 days after CD28SA stimulation,
were transferred into naı¨ve C57BL/6 mice. One day after cell transfer recipient mice received CD28SA injection. 3 days later cells were re-isolated and
analysed for proliferation, Foxp3 and IL-10 expression (black dots). Flow cytometric analysis of transferred T-cells with percentage of IL-10 producing
cells is depicted. Graphs show means 6 SD from 2–3 mice per group and results are representative of two independent experiments.
doi:10.1371/journal.pone.0050080.g005
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function was underscored by its ability to remove costimulatory
ligands (CD80, CD86) from APCs by trans-endocytosis [27].
In vivo CD28SA activated Tregs demonstrated dramatically
enhanced suppressor activity in vitro ([19], Fig. 3) and also in vivo
[19,28]. Importantly, we observed a particularly high, while IL-10
independent, suppressive activity within the IL-10 producing
subset of in vivo activated Tregs, correlating with their high level of
regulatory cell surface receptors.
Tissue-specific homing receptors were previously shown to be
upregulated on effector/memory-like Tregs [12,29]. In agreement
Figure 6. IL-10 producing Tregs are apoptosis prone. (A) CD4+CD25+ Tregs from CD28SA treated DEREG mice were isolated and stimulated
over night with anti-CD3, anti-CD28, IL-2. Next day cells were stained for IL-10 and separated into IL-10+Foxp3+ (black line) and IL-102Foxp3+ (grey
line) via FACS Sorter and cultured for 1 to 3 days with anti-CD3, anti-CD28, IL-2 and examined for Annexin V and 7AAD positive cells. As control
unseparated CD4+CD25+ T-cells (dashed line) were used. Graphs show means 6 SD from 3 individual experiments. ** p,0.005 compared IL-
10+Foxp3+ to IL-102Foxp3+ cells. (B) Flow cytometric analysis of costaining of Annexin V and clone 10-7A (phospholipids). (C) Binding of clone 10-7A
given in DMFI ( = MFI(marker)2MFI(isotype)) on gated CD4+ T-cells 3 days after CD28SA injection dependent on IL-10 and Foxp3 expression. Graphs
show means 6 SD from 3 or 5 mice assayed individually and results are representative of two independent experiments. ** p,0.005. (D) Gene
expression data given in M (ln(fold change)) of functional cluster ‘‘apoptosis’’ (DAVID) of sorted IL-10+ and IL-102 CD4+CD25+ Tregs 3 days after
stimulation. Transcripts selected for genes that showed $2-fold change and an adjusted p-value,0.001 (n = 2). (E) Bcl-2 expression of gated CD4+ T-
cells 3 days after CD28SA injection dependent on IL-10 and Foxp3 expression. * p,0.05. Results are representative of three independent experiments
with 3–4 mice.
doi:10.1371/journal.pone.0050080.g006
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with these reports, CD28SA stimulation downregulated the
lymphoid homing-receptor CCR7 [13], but upregulated the
inflammation-seeking receptor CCR5 and CCR6 [13,30,31] on
Tregs. In accordance with the view that polyclonally (CD28SA)
activated IL-10 producers are a correlate, at the population level,
of the few Tregs in unmanipulated mice producing IL-10 in
response to (self)antigens, these also expressed tissue-homing
receptors (CD103, CCR5, CCR6) consistent with their preferen-
tial recruitment to inflamed sites (Fig. 4A and data no shown).
A key finding of the present study is that after clonal expansion
and acquisition of IL-10 competence and tissue-homing capability,
most of these highly activated Tregs undergo apoptosis, and most
of the remaining cells lose the capacity to produce IL-10, ensuring
termination of immunosuppression after clearance of an infection.
The preferential apoptosis of IL-10 producing Tregs (Fig. 1E and
6A) is in line with the well-known link between extensive
proliferation and apoptosis [32]. Activation-induced cell death
depending in part on death receptor CD95 and its ligand CD95L
is one mechanism that controls the pool of conventional CD4+ T-
cells, but data regarding the sensitivity to CD95-mediated
apoptosis of Tregs are inconsistent [33,34]. For human Tregs it
was shown that effector/memory Tregs are highly sensitive to
apoptosis whereas naı¨ve/resting Tregs are more resistant [34]. In
line with this, we and others observed downregulation of the anti-
apoptotic protein Bcl-2 (Fig. 6E and [35]) and upregulation of
pro-apoptotic proteins like Bim or Caspase 3 in effector/memory-
like IL-10 producing Tregs after activation. However, upregula-
tion of CD95L was not accompanied by upregulation of CD95
(data not shown) after CD28SA stimulation. Furthermore it is
unlikely that IL-10 itself, which can induce apoptosis in several cell
types like mast cells, macrophages and CD4+ T cells from SLE
patients [36,37] is responsible for the preferential apoptosis of IL-
10 producing Tregs since in vivo CD28SA activated IL-10
producing and non-producing Tregs express comparable and
low levels of IL-10R (Fig. S3B). Thus, it is not clear yet which
mechanism(s) primarily drive(s) apoptosis of IL-10 producing
Tregs.
Taken together, our data connect clonal expansion, functional
differentiation as highlighted by competence for IL-10 production,
migration to inflamed sites, and programmed cell death within a
polyclonal wave of Treg activation. This sequence of events
correlates well with the striking efficacy of CD28SA treatment in a
broad spectrum of murine immune pathologies, and with the
return of the immune system to normality once Treg levels have
subsided in these models. While the unexpected cytokine release
syndrome induced by a human CD28SA [38], now traced back to
the stimulation of effector memory CD4 T-cells [39,40],
interrupted the development of this strategy in humans, transient
polyclonal Treg activation remains an attractive, and broadly
applicable approach for the future.
Materials and Methods
Ethics statement
All experiments were performed according to the German
regulations for animal experimentation and approved by the
Government of Lower Franconia as the responsible authority
(Permit Numbers 55.2-2531.01-64/07 and -64/11).
Mice
C57BL/6 (Harlan Winkelmann, Borchen, Germany), congenic
Thy1.1+C57BL/6 mice (Jackson Laboratories) and DEREG mice
generously provided by Tim Sparwasser [26] were bred in the
institute’s barrier-facility and used between 6–12 weeks of age.
In vivo expansion of T-cells by superagonistic anti-CD28
mAb
CD28SA (D665) [25] was bioreactor-produced in a low-
endotoxin format by Exbio, Prague, Czech Republic, Invivo
Biotech, Henningsdorf, Germany, or Serotec, Oxford, UK. PBS
was used as negative control. 200 mg per mouse was injected
intraperitoneally.
Flow cytometry
Fluorochrome-labeled or biotinylated Abs to the following
proteins were used: CD4 (RM4-5), CD25 (7D4), CD103 (M290),
CD62L (MEL-14), CD44 (Ly-24), CD45RB (16A), CD90.1 (OX-
7), GITR (DTA-1), ICOS (7E.17G9), CCR5 (C34-3448), CCR6
(140706), Bcl-2 (3FM) and IL-10 (JES5-16E3) from BD Biosci-
ences and LAP (TW7-16B4), IL-10R (1B1.3a) from BioLegend.
For intracellular IL-10 staining cells were restimulated with PMA
(0.1 mg/ml, Sigma-Aldrich), Ionomycin (1 mg/ml, Sigma-Aldrich)
and Golgistop (BD) for 4 hours, washed, fixed with Fix/Perm
Buffer from eBioscience and permeabilized with Perm Buffer (BD).
Foxp3 (FJK-16s), CCR7 (4B12), PD-1 (J43), CTLA-4 (UC10.4B9),
CD39 (24DMS1) and staining reagents from eBioscience were
used according to the manufacturer’s instructions. Acquisition was
performed on a FACSCaliburTM or BDTM LSR II and data were
analyzed using FlowJo software (TreeStar Inc, Ashland, OR,
USA). 10-7A is an IgM antibody generated from mice immunized
with a plasma membrane fraction isolated from CD28SA
activated rat Tregs. It was shown by ELISA (modified after [41])
that it is specific for phospholipids (phosphatidylethanolamine,
phosphatidylserine and cardiolipin). As secondary antibody we
used PE labeled anti-IgM (R6-60.2, BD).
Cell isolation and cell culture
Single-cell suspensions of lymph nodes were stained with a
cocktail of biotin-labeled antibodies (BD), followed by incubation
with Streptavidin MicroBeads. CD4+ T-cells were prepared by
negative selection using the MACS separation system (Miltenyi
Biotech). CD25+ and CD252 CD4+ T-cells were separated using
biotin-labeled anti-CD25 mAb (7D4) and Streptavidin MicroBe-
ads. IL-10 producing cells were stained with IL-10 Secretion Assay
(Cell Enrichment and Detection Kit) from Miltenyi Biotec
according to manufacturer’s instructions and sorted for IL-10
positive and negative cells via Cellsorter Vantage Diva. Cells were
cultured with anti-CD3 (145-2C11, 2 mg/ml, BD Biosciences),
anti-CD28 (E18, 5 mg/ml, Exbio, Prague, Czech Republic) and
recombinant human IL-2 (200 U/ml, Novartis, Basel, CH) for up
to three days. For detection of apoptosis cells were stained with
Annexin V and 7AAD (BD Biosciences).
Adoptive transfer
Purified CD4+ T-cells or purified IL-102 CD4+ T-cells of
untreated or CD28SA stimulated Thy1.1 mice (day 3) were
labeled with 10 mM CFSE (Invitrogen) at RT for 5 min. A total of
1.06107 cells in PBS were transferred i.v. one day before CD28SA
stimulation. Average cell division numbers (acd) were calculated as
S(% of cells in generation (n)6n)/100, (n = number of generation).
For conversion experiments purified CD4+ T-cells of DEREG
mice were FACS sorted for Foxp32(GFP2) cells. A total of
7.06106 cells in PBS were transferred i.v. into congenic Thy1.1
mice one day before CD28SA stimulation.
In vitro suppression assay
Isolated CD4+CD252 responder T-cells (56104) were CFSE
labeled and cultured for 3 days in U-bottomed 96-well plates with
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various dilutions of purified IL-10+, IL-102 or CD4+CD25+/
Foxp3+(GFP+) Tregs in the presence of soluble anti-CD3 (1 mg/
ml), irradiated splenic APC (20 Gy; 26105) and where mentioned
anti-IL-10R (1B1,2, 10 mg/ml). Proliferation was assayed by
CFSE dilution.
Microarray analysis
Total RNA was extracted from isolated IL-10+ and IL-102
CD4+CD25+ T-cells from C57BL/6 mice by TRIZOL (Invitro-
gen) method. Expression profiling analysis of RNA from IL10+
and IL-102 Tregs was performed on GeneChipH Mouse Genome
430 2.0 (Affymetrix, Santa Clara, CA). RNA quality was checked
using a BioAnalyzer (Agilent). RNA integrity numbers (RIN) of the
RNAs were between 9.4 and 9.6. Reverse transcription, second-
strand synthesis and cleanup of double-stranded cDNA were
performed according to the Affymetrix protocols (One-Cycle
cDNA synthesis Kit, Affymetrix, Santa Clara, CA) starting from
2 mg of total RNA. Data were analyzed using different R packages
from the Bioconductor project (www.bioconductor.org). Resulting
signal intensities were normalized by variance stabilization [42].
The quality of all data sets was tested by density plot and RNA
degradation plot. Statistical analysis to select differentially
expressed genes was performed using the LIMMA (Linear Models
for Microarray Analysis) package [43]. To find transcripts that
were different between two samples, we selected for genes that
showed a fold change of at least 2-fold to maximal 79-fold and an
adjusted p-value,0.001. To evaluate functional categories and to
map the selected genes to pathways DAVID (http://david.abcc.
ncifcrf.gov/home.jsp) database was used. The microarray data are
available in the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE41492.
Sponge implantation
Polyester-polyurethane sponges (565 mm2) (Vitaform Ltd,
Manchester, UK) containing heatkilled Listeria monocytogenes were
implanted s.c. in C57BL/6 mice [44]. After 4 days mice were
treated with 200 mg CD28SA or PBS i.p.. On day 7 sponges were
recovered, cells were washed out several times with BSS/BSA and
stained for Foxp3 and IL-10 via IL-10 Secretion Assay.
Statistical analysis
Data are presented as mean 6 SD. Statistical significance was
analyzed by unpaired t-test or Mann-Whitney U test using
GraphPad Prism Software. Values of p,0.05 were considered to
be statistically significant.
Supporting Information
Figure S1 Expression of migration related receptors of
Tregs after CD28SA injection. Percent of migration related
receptor positive cells in unstimulated Foxp3+ and Foxp32 CD4+
T-cells and 3 days after CD28SA stimulation in IL-10+ Foxp3+
(grey bar), IL-102Foxp3+ (white bar) and Foxp32 (black bar)
CD4+ T-cells. Graphs show means 6 SD from 3–4 mice assayed
individually and results are representative of two independent
experiments. * p,0.05, ns: no significant difference.
(TIF)
Figure S2 Characterisation of clone 10-7A. (A) Surface
staining of isolated in vivo CD28SA activated rat T-cells after 48 h
culture in medium+IL-2 with clone 10-7A and CD25. (B) ELISA,
which identified phosphatidylethanolamine, phosphatidylserine
and cardiolipin as target antigens for clone 10-7A mAb.
(TIF)
Figure S3 Expression of IL-10R and genes associated
with apoptosis. (A) Gene expression data of functional cluster
‘‘apoptosis’’ (DAVID) of sorted IL-10+ and IL-102 CD4+CD25+
Tregs 3 days after stimulation. Ratio: gene expression level of IL-
10+ to IL-102 CD4+CD25+ cells, M: ln(fold change). Transcripts
selected for genes that showed $2-fold change and an adjusted p-
value,0.001 (n = 2). (B) IL-10R expression of lymph node cells 3
days after CD28SA injection dependent on CD4, IL-10 and
Foxp3 expression. * p,0.05. Results are representative of two
independent experiments with 4–5 mice.
(TIF)
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